NR4A1 and breast cancer: However, while ASCO guidelines suggest a broad criterion for genetic testing, the actual practice in Italian BUs, as evidenced by our survey, shows a more selective approach: 48.6% of centers test all patients with triple-negative BC, and 89.0% of hormone-receptor-positive BC patients are initiated for BRCA testing primarily when they present with early-onset disease, multiple tumors, or a family history indicative of a genetic predisposition, highlighting a more tailored strategy that addresses specific patient profiles and risk factors.